IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.

Only around 80% of patients with generalized myasthenia gravis (MG) have serum antibodies to acetylcholine receptor [AChR; acetylcholine receptor antibody positive myasthenia gravis (AChR-MG)] by the radioimmunoprecipitation assay used worldwide. Antibodies to muscle specific kinase [MuSK; MuSK anti...

Full description

Bibliographic Details
Main Authors: Leite, M, Jacob, S, Viegas, S, Cossins, J, Clover, L, Morgan, B, Beeson, D, Willcox, N, Vincent, A
Format: Journal article
Language:English
Published: 2008
_version_ 1826267495646887936
author Leite, M
Jacob, S
Viegas, S
Cossins, J
Clover, L
Morgan, B
Beeson, D
Willcox, N
Vincent, A
author_facet Leite, M
Jacob, S
Viegas, S
Cossins, J
Clover, L
Morgan, B
Beeson, D
Willcox, N
Vincent, A
author_sort Leite, M
collection OXFORD
description Only around 80% of patients with generalized myasthenia gravis (MG) have serum antibodies to acetylcholine receptor [AChR; acetylcholine receptor antibody positive myasthenia gravis (AChR-MG)] by the radioimmunoprecipitation assay used worldwide. Antibodies to muscle specific kinase [MuSK; MuSK antibody positive myasthenia gravis (MuSK-MG)] make up a variable proportion of the remaining 20%. The patients with neither AChR nor MuSK antibodies are often called seronegative (seronegative MG, SNMG). There is accumulating evidence that SNMG patients are similar to AChR-MG in clinical features and thymic pathology. We hypothesized that SNMG patients have low-affinity antibodies to AChR that cannot be detected in solution phase assays, but would be detected by binding to the AChRs on the cell membrane, particularly if they were clustered at the high density that is found at the neuromuscular junction. We expressed recombinant AChR subunits with the clustering protein, rapsyn, in human embryonic kidney cells and tested for binding of antibodies by immunofluorescence. To identify AChRs, we tagged either AChR or rapsyn with enhanced green fluorescence protein, and visualized human antibodies with Alexa Fluor-labelled secondary or tertiary antibodies, or by fluorescence-activated cell sorter (FACS). We correlated the results with the thymic pathology where available. We detected AChR antibodies to rapsyn-clustered AChR in 66% (25/38) of sera previously negative for binding to AChR in solution and confirmed the results with FACS. The antibodies were mainly IgG1 subclass and showed ability to activate complement. In addition, there was a correlation between serum binding to clustered AChR and complement deposition on myoid cells in patients' thymus tissue. A similar approach was used to demonstrate that MuSK antibodies, although mainly IgG4, were partially IgG1 subclass and capable of activating complement when bound to MuSK on the cell surface. These observations throw new light on different forms of MG paving the way for improved diagnosis and management, and the approaches used have applicability to other antibody-mediated conditions.
first_indexed 2024-03-06T20:55:03Z
format Journal article
id oxford-uuid:38ec136b-5509-4be8-aca2-a7c72a21ec9f
institution University of Oxford
language English
last_indexed 2024-03-06T20:55:03Z
publishDate 2008
record_format dspace
spelling oxford-uuid:38ec136b-5509-4be8-aca2-a7c72a21ec9f2022-03-26T13:52:45ZIgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:38ec136b-5509-4be8-aca2-a7c72a21ec9fEnglishSymplectic Elements at Oxford2008Leite, MJacob, SViegas, SCossins, JClover, LMorgan, BBeeson, DWillcox, NVincent, AOnly around 80% of patients with generalized myasthenia gravis (MG) have serum antibodies to acetylcholine receptor [AChR; acetylcholine receptor antibody positive myasthenia gravis (AChR-MG)] by the radioimmunoprecipitation assay used worldwide. Antibodies to muscle specific kinase [MuSK; MuSK antibody positive myasthenia gravis (MuSK-MG)] make up a variable proportion of the remaining 20%. The patients with neither AChR nor MuSK antibodies are often called seronegative (seronegative MG, SNMG). There is accumulating evidence that SNMG patients are similar to AChR-MG in clinical features and thymic pathology. We hypothesized that SNMG patients have low-affinity antibodies to AChR that cannot be detected in solution phase assays, but would be detected by binding to the AChRs on the cell membrane, particularly if they were clustered at the high density that is found at the neuromuscular junction. We expressed recombinant AChR subunits with the clustering protein, rapsyn, in human embryonic kidney cells and tested for binding of antibodies by immunofluorescence. To identify AChRs, we tagged either AChR or rapsyn with enhanced green fluorescence protein, and visualized human antibodies with Alexa Fluor-labelled secondary or tertiary antibodies, or by fluorescence-activated cell sorter (FACS). We correlated the results with the thymic pathology where available. We detected AChR antibodies to rapsyn-clustered AChR in 66% (25/38) of sera previously negative for binding to AChR in solution and confirmed the results with FACS. The antibodies were mainly IgG1 subclass and showed ability to activate complement. In addition, there was a correlation between serum binding to clustered AChR and complement deposition on myoid cells in patients' thymus tissue. A similar approach was used to demonstrate that MuSK antibodies, although mainly IgG4, were partially IgG1 subclass and capable of activating complement when bound to MuSK on the cell surface. These observations throw new light on different forms of MG paving the way for improved diagnosis and management, and the approaches used have applicability to other antibody-mediated conditions.
spellingShingle Leite, M
Jacob, S
Viegas, S
Cossins, J
Clover, L
Morgan, B
Beeson, D
Willcox, N
Vincent, A
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
title IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
title_full IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
title_fullStr IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
title_full_unstemmed IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
title_short IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
title_sort igg1 antibodies to acetylcholine receptors in seronegative myasthenia gravis
work_keys_str_mv AT leitem igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT jacobs igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT viegass igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT cossinsj igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT cloverl igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT morganb igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT beesond igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT willcoxn igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis
AT vincenta igg1antibodiestoacetylcholinereceptorsinseronegativemyastheniagravis